MAximising Therapeutic Utility in Rheumatoid Arthritis
Toggle navigation
Home
Our Research
TranSMART
About Us
About Us
Academic and Industry Partners
News and publications
Patient/Public Involvment
What is MATURA?
EPIC-RA – Patient Survey
Get Involved MPAG
Highlights and News
Jargon buster
Synovial biopsy: patient interview
Contact Us
Highlights and News
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA ... - Nature.com
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA ...
Nature.com
Are innovation and new technologies in precision medicine paving a new era in patients centric care? - Journal of ... - Journal of Translational Medicine
Are innovation and new technologies in precision medicine paving a new era in patients centric care? - Journal of ...
Journal of Translational Medicine
Systems-biology analysis of rheumatoid arthritis fibroblast-like synoviocytes implicates cell line-specific transcription ... - Nature.com
Systems-biology analysis of rheumatoid arthritis fibroblast-like synoviocytes implicates cell line-specific transcription ...
Nature.com
Related
What is MATURA?
EPIC-RA – Patient Survey
Get Involved MPAG
Highlights and News
The MATURA consortium
includes academic groups and industry partners working together to identify and test biomarkers
predictive of response to biological therapy in patients with rheumatoid arthritis
Home
| Copyright © Experimental Medicine & Rheumatology Department, Queen Mary University London, 2015 - 2024 |
Sitemap